Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Inhibitors

All categories
DBCAT003788Pharmacologic class

A DrugBank category of 3 drugs. 3 of them are approved.

Drugs

What you can answer from here — as of November 29, 2022

3DrugsEach linked to its full drug card
Listed above
1Drug targetEvery drug–target pair in the class, with bond type
Sign in
96Marketed productsAcross the regions we cover, with dosage forms and routes
Sign in
2Routes of administrationHow the drugs in this class are given
Sign in

Which targets do Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Inhibitors share, and which companies have late-stage candidates in this class?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In